azelnidipine has been researched along with 8-epi-prostaglandin f2alpha in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, S; Mori, T; Nako, K; Ogawa, S | 1 |
| Eguchi, K; Ishikawa, J; Kario, K; Matsui, Y; Shimada, K | 1 |
2 trial(s) available for azelnidipine and 8-epi-prostaglandin f2alpha
| Article | Year |
|---|---|
Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Azetidinecarboxylic Acid; C-Reactive Protein; Calcium Channel Blockers; Creatinine; Deoxyguanosine; Diabetic Nephropathies; Dihydropyridines; Dinoprost; Drug Therapy, Combination; Female; Humans; Interleukin-6; Male; Middle Aged; Oxidative Stress | 2008 |
Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin Receptor Antagonists; Azetidinecarboxylic Acid; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Creatinine; Dihydropyridines; Dinoprost; Diuretics; Female; Humans; Imidazoles; Male; Middle Aged; Sleep; Tetrazoles | 2011 |